Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jadohealth.2024.07.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Breathing Easy in Maricopa County, Arizona: Empowering K-12 Schools With a Novel Nurse Coaching Model to Facilitate Implementation of a County-Wide School-Based Stock Albuterol Inhaler Program.
J Sch Nurs
January 2025
Office of Population Health Sciences, University of Illinois Chicago, Chicago, IL, USA.
To reduce chronic school absenteeism and morbidity and mortality among school-aged children, the prompt administration of albuterol sulfate in schools remains vital. School-based stock inhaler programs are a practical approach to ensure equitable access to life-saving rescue medication for students. School and community partnerships can potentially strengthen program implementation and fidelity by integrating evidence-based practices into routine care.
View Article and Find Full Text PDFBreaking Barriers: Addressing Gender Disparities in Hip Resurfacing Surgery Access in the United States.
Arch Bone Jt Surg
January 2024
Orthopedic Research Center, Department of Orthopedic Surgery, Mashhad University of Medical sciences, Mashhad, Iran.
Second-generation large-diameter head hip resurfacing (HR) arthroplasty has gained popularity in terms of its potential for minimal wear and the preservation of proximal femoral bone stock. HR faces challenges, such as increased hip fracture rates and adverse reactions to metal detritus, despite the fact that over one million metal-on-metal (MoM) arthroplasties have been performed globally. FDA issued warnings in 2011 and 2016 regarding higher failure rates in women and categorized MoM implants as high-risk, influencing U.
View Article and Find Full Text PDFCoronavirus Disease 2019 (COVID-19) Real World Data Infrastructure: A Big-Data Resource for Study of the Impact of COVID-19 in Patient Populations With Immunocompromising Conditions.
Open Forum Infect Dis
January 2025
Northwell, Department of Pathology and Laboratory Medicine, New Hyde Park, New York, USA.
Background: We developed a United States-based real-world data resource to better understand the continued impact of the coronavirus disease 2019 (COVID-19) pandemic on immunocompromised patients, who are typically underrepresented in prospective studies and clinical trials.
Methods: The COVID-19 Real World Data infrastructure (CRWDi) was created by linking and harmonizing de-identified HealthVerity medical and pharmacy claims data from 1 December 2018 to 31 December 2023, with severe acute respiratory syndrome coronavirus 2 virologic and serologic laboratory data from major commercial laboratories and Northwell Health; COVID-19 vaccination data; and, for patients with cancer, 2010 to 2021 National Cancer Institute Surveillance, Epidemiology, and End Results registry data.
Results: The CRWDi contains 4 cohorts: patients with cancer; patients with rheumatic diseases receiving pharmacotherapy; noncancer solid organ and hematopoietic stem cell transplant recipients; and people from the general population including adults and pediatric patients.
Analysis of choroidal markers of activity in pachychoroid disease spectrum.
Graefes Arch Clin Exp Ophthalmol
January 2025
Londrina State University, Avenida Robert Koch, 60, Londrina, CEP 86038-440, Paraná, Brazil.
Purpose: To detect choroidal markers of disease activity in eyes with chronic active unilateral pachychoroid disease spectrum (PDS) compared to the non-active contralateral eyes, based on multimodal imaging and particularly indocyanine green angiography (ICGA).
Methods: An observational retrospective case-control study. The study evaluated individuals diagnosed with chronic active unilateral PDS (group 1) by comparing the eyes with the non-active fellow eyes (group 2).
Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant.
Sci Rep
January 2025
Division of Hematology and Oncology, University of California, 1450 3rd Street, San Francisco, CA, 94143, USA.
For individuals at high risk of developing breast cancer, interventions to mitigate this risk include surgical removal of their breasts and ovaries or five years treatment with the anti-estrogen tamoxifen or aromatase inhibitors. We hypothesized that a silicone based anti-estrogen-eluting implant placed within the breast would provide the risk reduction benefit of hormonal therapy, but without the adverse effects that limit compliance. To this end, we demonstrate that when placed adjacent to mammary tissue in the 7,12-dimethylbenz[a]anthracene-induced rat breast cancer model a fulvestrant-eluting implant delays breast cancer with minimal systemic exposure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!